These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 29923053

  • 1. Reduced expression of DNA repair genes and chemosensitivity in 1p19q codeleted lower-grade gliomas.
    Tang L, Deng L, Bai HX, Sun J, Neale N, Wu J, Wang Y, Chang K, Huang RY, Zhang PJ, Li X, Xiao B, Cao Y, Tao Y, Yang L.
    J Neurooncol; 2018 Sep; 139(3):563-571. PubMed ID: 29923053
    [Abstract] [Full Text] [Related]

  • 2. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
    Chai RC, Zhang KN, Chang YZ, Wu F, Liu YQ, Zhao Z, Wang KY, Chang YH, Jiang T, Wang YZ.
    Carcinogenesis; 2019 Oct 16; 40(10):1229-1239. PubMed ID: 31157866
    [Abstract] [Full Text] [Related]

  • 3. Conventional Magnetic Resonance Features for Predicting 1p19q Codeletion Status of World Health Organization Grade II and III Diffuse Gliomas.
    Peng X, Yishuang C, Kaizhou Z, Xiao L, Ma C.
    J Comput Assist Tomogr; 2019 Oct 16; 43(2):269-276. PubMed ID: 30371623
    [Abstract] [Full Text] [Related]

  • 4. Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.
    Branzoli F, Pontoizeau C, Tchara L, Di Stefano AL, Kamoun A, Deelchand DK, Valabrègue R, Lehéricy S, Sanson M, Ottolenghi C, Marjańska M.
    Neuro Oncol; 2019 Jun 10; 21(6):765-774. PubMed ID: 30726924
    [Abstract] [Full Text] [Related]

  • 5. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
    McDuff SGR, Dietrich J, Atkins KM, Oh KS, Loeffler JS, Shih HA.
    Cancer Med; 2020 Jan 10; 9(1):3-11. PubMed ID: 31701682
    [Abstract] [Full Text] [Related]

  • 6. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE, Caron AA, Decker PA, Jenkins RB, Lachance DH, Giannini C.
    Oncotarget; 2015 Oct 06; 6(30):30295-305. PubMed ID: 26210286
    [Abstract] [Full Text] [Related]

  • 7. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
    Speirs CK, Simpson JR, Robinson CG, DeWees TA, Tran DD, Linette G, Chicoine MR, Dacey RG, Rich KM, Dowling JL, Leuthardt EC, Zipfel GJ, Kim AH, Huang J.
    Int J Radiat Oncol Biol Phys; 2015 Feb 01; 91(2):268-76. PubMed ID: 25636755
    [Abstract] [Full Text] [Related]

  • 8. [Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice].
    Fontaine D, Vandenbos F, Lebrun C, Paquis V, Frenay M.
    Rev Neurol (Paris); 2008 Feb 01; 164(6-7):595-604. PubMed ID: 18565359
    [Abstract] [Full Text] [Related]

  • 9. 1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas.
    Zhang Y, Xie Y, He L, Tang J, He Q, Cao Q, Cui L, Guo W, Hua K, Dimberg A, Wang L, Zhang L.
    Cell Oncol (Dordr); 2021 Feb 01; 44(1):193-204. PubMed ID: 32915415
    [Abstract] [Full Text] [Related]

  • 10. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
    Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard MA, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon JM, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre JY, Hoang-Xuan K.
    Neurology; 2007 May 22; 68(21):1831-6. PubMed ID: 17515545
    [Abstract] [Full Text] [Related]

  • 11. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z, Lan Y, Wang L, Ge J, Wang J, Liu F, He Z, Zhang H, Luo M, Lin D, Tan Y, Xu Y, Luo T.
    BMC Cancer; 2020 Nov 09; 20(1):1072. PubMed ID: 33167941
    [Abstract] [Full Text] [Related]

  • 12. MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
    Zhou H, Vallières M, Bai HX, Su C, Tang H, Oldridge D, Zhang Z, Xiao B, Liao W, Tao Y, Zhou J, Zhang P, Yang L.
    Neuro Oncol; 2017 Jun 01; 19(6):862-870. PubMed ID: 28339588
    [Abstract] [Full Text] [Related]

  • 13. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.
    Yamauchi T, Ohno M, Matsushita Y, Takahashi M, Miyakita Y, Kitagawa Y, Kondo E, Tsushita N, Satomi K, Yoshida A, Ichimura K, Narita Y.
    Brain Tumor Pathol; 2018 Jul 01; 35(3):148-158. PubMed ID: 29922974
    [Abstract] [Full Text] [Related]

  • 14. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade.
    Iwadate Y, Matsutani T, Hara A, Hirono S, Ikegami S, Kobayashi M, Ito D, Kawauchi D, Horiguchi K, Tamiya A, Higuchi Y.
    J Neurooncol; 2019 Jan 01; 141(1):205-211. PubMed ID: 30565028
    [Abstract] [Full Text] [Related]

  • 15. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
    Sabha N, Knobbe CB, Maganti M, Al Omar S, Bernstein M, Cairns R, Çako B, von Deimling A, Capper D, Mak TW, Kiehl TR, Carvalho P, Garrett E, Perry A, Zadeh G, Guha A, Sidney Croul.
    Neuro Oncol; 2014 Jul 01; 16(7):914-23. PubMed ID: 24470545
    [Abstract] [Full Text] [Related]

  • 16. Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas.
    Alentorn A, van Thuijl HF, Marie Y, Alshehhi H, Carpentier C, Boisselier B, Laigle-Donadey F, Mokhtari K, Scheinin I, Wesseling P, Ylstra B, Capelle L, Hoang-Xuan K, Sanson M, Delattre JY, Reijneveld JC, Idbaih A.
    Neuro Oncol; 2014 Mar 01; 16(3):400-8. PubMed ID: 24335697
    [Abstract] [Full Text] [Related]

  • 17. Molecular-genetic and clinicopathological prognostic factors in patients with gliomas showing total 1p19q loss: gain of chromosome 19p and histological grade III negatively correlate with patient's prognosis.
    Hayashi S, Kitamura Y, Hirose Y, Yoshida K, Sasaki H.
    J Neurooncol; 2017 Mar 01; 132(1):119-126. PubMed ID: 28025770
    [Abstract] [Full Text] [Related]

  • 18. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T, Sonoda Y, Shibahara I, Saito R, Kanamori M, Kumabe T, Tominaga T.
    J Neurooncol; 2016 Sep 01; 129(3):505-514. PubMed ID: 27401154
    [Abstract] [Full Text] [Related]

  • 19. Loss of genetic material within 1p and 19q chromosomal arms in low grade gliomas of central nervous system.
    Ręcławowicz D, Stempniewicz M, Biernat W, Limon J, Słoniewski P.
    Folia Neuropathol; 2013 Sep 01; 51(1):26-32. PubMed ID: 23553134
    [Abstract] [Full Text] [Related]

  • 20. Prediction of IDH1-Mutation and 1p/19q-Codeletion Status Using Preoperative MR Imaging Phenotypes in Lower Grade Gliomas.
    Park YW, Han K, Ahn SS, Bae S, Choi YS, Chang JH, Kim SH, Kang SG, Lee SK.
    AJNR Am J Neuroradiol; 2018 Jan 01; 39(1):37-42. PubMed ID: 29122763
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.